Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation

References

• Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216–2222.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452–459.
   PubMed Web of Science ®Google Scholar
• Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients 1-45 years. Blood. 2018;131(22):2475–2484.
   PubMed Web of Science ®Google Scholar
• Lauw MN, van der Holt B, Middeldorp S, et al. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: effect of fresh frozen plasma supplementation. Thromb Haemost. 2013;109(4):633–642.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Chevallier P, Delaine M, et al.; GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang). Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adults patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93(10):1488–1494.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744–2750.
   PubMed Web of Science ®Google Scholar
• Liebman HA, Wada JK, Patch MJ, et al. Depression of functional and antigeneic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer. 1982;50(3):451–456.
   PubMed Web of Science ®Google Scholar
• Mitchell LG, Halton JM, Vegh PA, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol. 1994;16(2):120–126.
   PubMedGoogle Scholar
• Mitchell L, Hoogendoorn H, Giles AR, et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L’asparaginase-induced antithrombin III deficiency. Blood. 1994;83(2):386–391.
   PubMed Web of Science ®Google Scholar
• Kuhle S, Lau A, Bajzar L, et al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol. 2006;134(5):526–531.
   PubMed Web of Science ®Google Scholar
• Abbott LS, Deevska M, Fernandez CV, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood. 2009;114(25):5146–5151.
   PubMed Web of Science ®Google Scholar
• Grace RF, DeAngelo DJ, Stevenson KE, et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018;45(2):306–314.
   PubMed Web of Science ®Google Scholar
• Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2001;12(5):367–370.
   PubMed Web of Science ®Google Scholar
• Greiner J, Schrappe M, Claviez A, et al. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019;104(4):756–765.
   PubMed Web of Science ®Google Scholar
• Gugliotta L, D'Angelo A, Mattioli Belmonte M, et al. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol. 1990;74(4):465–470.
   PubMed Web of Science ®Google Scholar
• Belmonte MM, Gugliotta L, Delvos U, et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase. Haematologica. 1991;76(3):209–214.
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Gugliotta I, Leone G, et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukemia patients treated with a low dose of Escherichia coli L-asparaginase. A Gimema study. Blood Coagul Fibrinolysis. 1994;5(1):23–28.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Wolf RC, Hook CC, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma. 2004;45(8):1545–1549.
   PubMed Web of Science ®Google Scholar
• Farrell K, Fyfe A, Allan J, et al. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leuk Lymphoma. 2016;57(11):2568–2574.
   PubMed Web of Science ®Google Scholar
• Barreto JN, McCullough KB, Peskey CS, et al. Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. Leuk Lymphoma. 2017;58(11):2588–2597.
   PubMed Web of Science ®Google Scholar
• Chen J, Ngo D, Aldoss I, et al. Antithrombin supplementation did not impact the incidence of asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(5):1187–1192.
   PubMed Web of Science ®Google Scholar
• Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003;90(2):235–244.
   Google Scholar
• Ranta S, Heyman MM, Jahnukainen K, et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2013;24(7):749–756.
   PubMed Web of Science ®Google Scholar
• Meister B, Kropshofer G, Klein-Franke A, et al. Comparison of low-molecular weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(2):298–303.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
   Google Scholar
• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548–1559.
   PubMed Web of Science ®Google Scholar
• ECOG-ACRIN Cancer Research Group. E1910 – A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults. Available at: https://ecog-acrin.org/clinical-trials/e1910-educational-materials
   Google Scholar
• Thrombate III [package insert]. Research Triangle Park, NC: Grifols Therapeutics, Inc; 2019.
   Google Scholar
• Couturier M-A, Huguet F, Chevallier P, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with L-asparaginase: the GRAALL experience. Am J Hematol. 2015;90(11):986–991.
   PubMed Web of Science ®Google Scholar
• Nowak-Göttl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003;101(7):2529–2533.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di Castelnuovo A, et al. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost. 2007;5(3):621–623.
   PubMed Web of Science ®Google Scholar
• Hernandez-Espinosa D, Minano A, Ordonez A, et al. Dexamethasone induces a heat-stress response that ameliorates the conformational consequences on antithrombin of L-asparaginase treatment. J Thromb Haemost. 2009;7:1128–1133.
   PubMed Web of Science ®Google Scholar
• Gugliotta L, Mazzucconi MG, Leone G, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastuic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. Eur J Haematol. 1992;49(2):63–66.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375–380.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Li D, Mitchell L, et al. PREVAPIX-ALL: Apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukemia (ALL) – rationale and design. Thromb Haemost. 2019;119(05):844–853.
   PubMedGoogle Scholar
• Plander M, Szendrei T, Bodo I, et al. Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment. Ann Hematol. 2015;94(7):1257–1258.
   PubMed Web of Science ®Google Scholar
• Talamo L, Douvas M, Macik BG, et al. Successful treatment with apixaban of sinus thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management. Ann Hematol. 2017;96(4):691–693.
   PubMed Web of Science ®Google Scholar